Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery (www.genengnews.com)

Boltz PBC has officially launched with a $28 million seed funding round, aiming to democratize AI platforms for drug discovery. The company, co-founded by recent MIT PhD graduates, has developed a series of AI models starting with Boltz-1, which achieves AlphaFold 3-level accuracy in predicting biomolecular structures. Their subsequent models, Boltz-2 and BoltzGen, have made significant strides in accurate binding affinity predictions and therapeutic design, with over 100,000 scientists adopting their tools to enhance drug discovery processes. What sets Boltz apart is its commitment to open science and accessibility, allowing researchers to transition from therapeutic hypotheses to viable drug candidates entirely on their computers. Boltz's platform, Boltz Lab, addresses critical bottlenecks in drug development, such as computational costs and user experience. Their collaboration with Pfizer will further enhance their AI models using proprietary data, reinforcing the importance of developing user-friendly, scalable solutions for scientific workflows. By advocating for an open-source approach, Boltz aims to shift the drug discovery landscape towards a more collaborative, efficient model that prioritizes widespread access over proprietary technologies.